All Stories

  1. Pregabalin in Pregnancy
  2. Older Brothers and Male Homosexuality: Antibodies as an Explanation
  3. Ketamine as anaesthesia for ECT: is there room to improve a gold standard treatment?
  4. Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem
  5. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: Systematic review and meta-analysis of randomized controlled trials
  6. A simple rearrangement can improve visual understanding of a Forest plot
  7. Theoretical and practical issues related to the management of severe and refractory psychotic illness complicated by pulmonary embolism
  8. A Critical Examination of Studies on Curcumin for Depression
  9. Antidepressant Augmentation With Anti-Inflammatory Agents
  10. Images in Electroconvulsive Therapy
  11. Images in Electroconvulsive Therapy
  12. Cause Versus Association in Observational Studies in Psychopharmacology
  13. Musical obsessions: A comprehensive review of neglected clinical phenomena
  14. Nonsteroidal Anti-inflammatory Drugs and 5-HT 3 Serotonin Receptor Antagonists as Innovative Antipsychotic Augmentation Treatments for Schizophrenia
  15. A Primer for the Conceptualization of the Mechanism of Action of Electroconvulsive Therapy, 2: Organizing the Information
  16. Electroconvulsive Therapy, Hypertensive Surge, Blood-Brain Barrier Breach, and Amnesia
  17. Searching for the Mechanism(s) of ECT’s Therapeutic Effect
  18. A Primer for the Conceptualization of the Mechanism of Action of Electroconvulsive Therapy, 1: Defining the Question
  19. Cardiovascular adverse effects of newer antidepressants
  20. Potentially Significant Versus Clinically Significant Drug Interactions: Pomegranate Juice as a Case in Point
  21. Antidepressants and Testicular Cancer: Cause Versus Association
  22. Selective Serotonin Reuptake Inhibitor Drug Interactions in Patients Receiving Statins
  23. Bilateral peripheral edema as a rare adverse effect of escitalopram
  24. Moving psychopharmacological drug development to the developing world
  25. Dancing mind - Promoting mental health through the medium of movement
  26. Rapid, illegible handwriting as a symptom of obsessive-compulsive disorder
  27. Policy of the Indian Journal of Psychiatry on the problem of plagiarism
  28. Unilateral galactorrhea associated with low-dose escitalopram
  29. Augmenting Selective Serotonin Reuptake Inhibitors With Clomipramine in Obsessive-Compulsive Disorder: Benefits and Risks
  30. Reversible abnormality of the splenium in a bipolar patient with neuroleptic malignant syndrome
  31. Transcranial Direct Current Stimulation for Refractory Auditory Hallucinations in Schizophrenia
  32. Learning From History: How to Swallow a Pill
  33. Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins
  34. Famotidine Augmentation in Schizophrenia: Hope or Hype?
  35. Antidepressant Use in Pregnancy and Risk of Autism Spectrum Disorders: A Critical Examination of the Evidence
  36. Electroconvulsive Therapy Attenuates Dendritic Arborization in the Basolateral Amygdala
  37. Once- to Twice-Daily, 3-Year Domiciliary Maintenance Transcranial Direct Current Stimulation for Severe, Disabling, Clozapine-Refractory Continuous Auditory Hallucinations in Schizophrenia
  38. Levothyroxine in Psychiatry
  39. Antenatal Exposure to Selective Serotonin Reuptake Inhibitors and Duration of Gestation
  40. Low-Dose Amisulpride and Elevation in Serum Prolactin
  41. Signal-to-Noise Ratio, Variability, and Their Relevance in Clinical Trials
  42. Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure
  43. Antidepressant Action of Atypical Antipsychotics
  44. Augmentation of Venlafaxine With Bupropion
  45. Drug Interactions in the Treatment of Depression in Patients Receiving β-Blocker Drugs
  46. Prolonged, self-administration of ultra-high doses of quetiapine
  47. Screening for disease, psychological testing, and psychotherapy Looking behind the mirror
  48. Ejaculatory dysfunction associated with low dose amisulpride
  49. Anesthesiological training and certification for psychiatrists practising unmodified ECT
  50. Ethical issues in psychiatry research: Special concerns for India
  51. How to read a research paper: Ecological validity, apples, and oranges
  52. Ventricular premature contractions associated with iloperidone
  53. Images in electroconvulsive therapy: Pilot impressions suggesting that ECT reduces excitatory synapses in the basolateral amygdala
  54. Drug Interactions in the Treatment of Depression in Patients With Ischemic Heart Disease
  55. Serotonin Reuptake Inhibitor Treatment of Obsessive-Compulsive Symptoms in Clozapine-Medicated Schizophrenia
  56. Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study
  57. There’s More to Placebo-Related Improvement Than the Placebo Effect Alone
  58. Antipsychotic Drugs and Myocardial Infarction in Patients With Dementia
  59. Age, Statin Use, and the Risk for Incident Parkinson Disease
  60. Hyperactive sexual desire in Klinefelter Syndrome: Treatment with sertraline
  61. Breast Cancer and Antidepressant Use
  62. Is Sitting Harmful to Health? It Is Too Early to Say
  63. Modafinil and Armodafinil in Schizophrenia
  64. Do Angiotensin Receptor Blockers Really Hold Promise for the Improvement of Cognitive Functioning?
  65. Drugs That Escape Hepatic Metabolism
  66. Schizophrenia and Smoking
  67. Black Tea and Blood Pressure: Did the Blood Pressure Fall or Rise?
  68. Decreasing Adverse Outcomes Associated With Unmodified ECT
  69. Electrical Parameters and the Efficacy of ECT
  70. Maintenance ECT as a Therapeutic Approach to Medication-Refractory Epilepsy in an Adult With Mental Retardation
  71. Selective Serotonin Reuptake Inhibitors and Persistent Pulmonary Hypertension of the Newborn
  72. Continuation of ECT After Recovery From Transient, ECT-Induced, Postictal Cortical Blindness
  73. Emergence of psychotic symptoms during Internet withdrawal
  74. Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder
  75. Suicide: An Indian perspective
  76. Psychopharmacology of schizophrenia: The future looks bleak
  77. Behavioral interventions for insomnia: Theory and practice
  78. Covert medication: Do means justify the ends?
  79. Investigation of the possible role of Shankapushpi in the attenuation of ECT induced amnestic deficits
  80. Position statement and guidelines on unmodified electroconvulsive therapy
  81. Electroconvulsive Therapy for Posttraumatic Stress Disorder
  82. Odd Odds
  83. Administration of a selective glucocorticoid antagonist attenuates electroconvulsive shock-induced retrograde amnesia
  84. Electroconvulsive Therapy
  85. Standard operating procedures for clinical practice
  86. Lorazepam-induced prolonged apnea after ECT-induced prolonged seizure
  87. Prayer, randomized controlled trials and distance healing: A response to Dr. Jana
  88. Exploring new frontiers in neuropsychopharmacology: SSRIs for stroke
  89. How to read a research paper: Reading between and beyond the lines
  90. The MMR vaccine and autism: Sensation, refutation, retraction, and fraud
  91. How to write a good abstract for a scientific paper or conference presentation
  92. Placeboxetine for major depressive disorder: Researcher, author, reader, and reviewer perspectives on randomized controlled trials
  93. Development of a murine animal model of depression for repeated dosing with human interferon alpha
  94. A 6-week, multicentre, randomized controlled clinical trial to evaluate the safety and efficacy of placeboxetine hydrochloride in the treatment of major depressive disorder in an Indian setting
  95. Serotonin Reuptake Inhibitor Antidepressants and Abnormal Bleeding
  96. Electroconvulsive Therapy in a Patient With Klippel-Trenaunay-Weber Syndrome Complicated by Partial Popliteal Vein Thrombosis
  97. Uneventful use of haloperidol and trihehexyphenidyl during three consecutive pregnancies
  98. Variations on a Theme of Unmodified Electroconvulsive Therapy
  99. The Depiction of Electroconvulsive Therapy in Hindi Cinema
  100. The Safety and Efficacy of Benzodiazepine-Modified Treatments as a Special Form of Unmodified ECT
  101. A Survey of the Practice of Electroconvulsive Therapy in Asia
  102. The Practice of Electroconvulsive Therapy in Asia
  103. Continuing medical education: SSRIs and pregnancy
  104. Primary prevention for offspring of parents with mental illness
  105. Dose calculation with brief-pulse ECT demystified
  106. Innovative approaches to treatment - refractory depression: The ketamine story
  107. Prayer, randomized controlled trials and healing: A response to Prof. Abraham Verghese
  108. Stahl′s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications
  109. Efficacy of ECT in Chronic, Severe, Antidepressant- and CBT-Refractory PTSD: An Open, Prospective Study
  110. The evolution of Indian psychiatric research: An examination of the early decades of the Indian journal of Psychiatry
  111. Lithium, trifluperazine and idiopathic leucopenia: Author and reviewer perspectives on how to write a good case report
  112. How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy
  113. Familial vulnerability to an unusual cognitive adverse effect of topiramate: Discussion of mechanisms
  114. Maintenance Electroconvulsive Therapy
  115. Desvenlafaxine
  116. Depression and schizophrenia
  117. Postgraduate corner: Continuing medical education: Psychopharmacology
  118. Teratogenicity and hyperprolactinemia
  119. Prayer and healing: A medical and scientific perspective on randomized controlled trials
  120. Ashwagandha for anxiety disorders
  121. Melatonin treatment of shoulder-and-neck dyskinesia possibly related to fluoxetine treatment
  122. Systematic enhancement of functioning as a therapeutic technique in conversion disorder
  123. Leukopenia and thrombocytopenia on adding aripiprazole to phenytoin
  124. The prevention and treatment of cognitive decline and dementia: An overview of recent research on experimental treatments
  125. Celecoxib as an in vivo probe of cyclooxygenase-2 mechanisms underlying retrograde amnesia in an animal model of ECT
  126. The Ebbinghaus retention curve: training does not increase the ability to apply pressure immobilisation in simulated snake bite—implications for snake bite first aid in the developing world
  127. Successful use of maintenance rTMS for 8 months in a patient with antipsychotic-refractory auditory hallucinations
  128. Pharmacological Attenuation of Electroconvulsive Therapy-Induced Cognitive Deficits
  129. Continuing medical education
  130. Postgraduate corner: Continuing medical education
  131. The National Institute of Open Schooling
  132. Post-graduate CME
  133. Schizophrenia, Osteoporosis, and an Examination of the Risk of Fractures in Patients Receiving ECT
  134. Unilateral Nondominant Electrode Placement as a Risk Factor for Recall of Awareness Under Anesthesia During Electroconvulsive Therapy
  135. First- vs Second-Generation Antipsychotic Drugs in Schizophrenia
  136. The Influence of Name on the Acceptability of ECT
  137. Safety of Repeated Courses of Electroconvulsive Therapy in a Patient With Harrington Rods
  138. ECT Practice in Asia
  139. Melatonin in Schizophrenic Outpatients With Insomnia
  140. Confounding
  141. Glucocorticoid mechanisms may contribute to ECT-induced retrograde amnesia
  142. Electroconvulsive Therapy in India
  143. Cortical Blindness Associated With Electroconvulsive Therapy
  144. Aripiprazole use in a pregnant schizoaffective woman
  145. Simultaneous True Seizures and Pseudoseizures
  146. ECT for Treatment-Resistant Schizophrenia
  147. Sore throat and obsessions: A causal link?
  148. Anti-amnestic properties of Brahmi and Mandookaparni in a rat model
  149. The case for humour: Moving one step further
  150. Controversy revisited: selective serotonin reuptake inhibitors in paediatric depression
  151. ECT Devices in India
  152. Knowledge About and Attitudes Towards ECT: Methodological Issues
  153. Why Some Psychiatrists May Be Unwilling To Receive Electroconvulsive Therapy
  154. Australasian commentary on CANMAT guidelines for treatment of bipolar disorder
  155. In Vigorous Defense of Whole Brain Kindling and a Reconsideration on Naming the Phenomenon
  156. The risk of harm in mania and the very early time course of improvement: important but neglected variables in treatment research
  157. Tumor Necrosis Factor-Alpha, Depression, and ECT: Toward a Better Understanding of the Relationships
  158. Possible Impact of Dropout in a Study of High-Dose Olanzapine and Prolactin Levels
  159. Antidepressant-Withdrawal Mania
  160. Multiple Expansion Disorder
  161. Spectral EEG Effects of Electroconvulsive Shock Stimulus Parameters
  162. The Dilemma of Unmodified Electroconvulsive Therapy
  163. Need for Homogeneity of Diagnosis in Studies on the Cognitive Effects of ECT
  164. Does Absolute Charge Administered Predict Speed of Response to Right Unilateral ECT?
  165. Confirmation of Whole-Brain Kindling With Repeated Subthreshold Electroconvulsive Shocks: A Controlled Study
  166. ECS Seizure Threshold: Normal Variations, and Kindling Effects of Subconvulsive Stimuli
  167. Pharmacological Treatment of Severe Psychiatric Disorders in the Developing World
  168. ECT in the management of major depression: Implications of recent research
  169. Effect of Stimulus Intensity and Number of Treatments on ECS-Related Seizure Duration and Retrograde Amnesia in Rats
  170. Continuation and Maintenance ECT: A Review of Recent Research
  171. ECT in Poetry: In a Lighter Vein
  172. Effects of Pulse Amplitude, Pulse Frequency, and Stimulus Duration on Seizure Threshold: A Laboratory Investigation
  173. Zolpidem, vascular headache, and hallucinations in an adolescent
  174. High But Not Low ECS Stimulus Intensity Augments Apomorphine-Stimulated Dopamine Postsynaptic Receptor Functioning in Rats
  175. Memory protective effect of indomethacin against electroconvulsive shock-induced retrograde amnesia in rats
  176. Effects of Stimulus Parameters on Seizure Duration and ECS-Induced Retrograde Amnesia
  177. GS-02 for Dysthymic Disorder
  178. GS-02 for Dysthymic Disorder
  179. Phenylephrine and ECS-Induced Retrograde Amnesia
  180. Effect of innate direction bias on T-maze learning in rats: implications for research
  181. Confusion and dysphoria with low‐dose topiramate in a patient with bipolar disorder
  182. A Preliminary Survey of Rhinotillexomania in an Adolescent Sample
  183. Quantifying the ECT Dose: The Right Unit Remains Elusive
  184. Nitroprusside and ECS-Induced Retrograde Amnesia
  185. Melatonin in Medically Ill Patients With Insomnia
  186. Electroconvulsive Therapy and the Alpha-2 Noradrenergic Receptor: Implications of Treatment Schedule Effects
  187. Herbal Treatments for ECS-Induced Memory Deficits: A Review of Research and a Discussion on Animal Models
  188. A Simplified Herbal Formulation Attenuates Electroconvulsive Shock-Induced Anterograde Amnesia
  189. Reply to "Obsessive-Compulsive Symptoms With Risperidone"
  190. Duration of Liquid Fast Before ECT
  191. Attenuation of ECS-Induced Retrograde Amnesia by Using an Herbal Formulation
  192. Risperidone May Worsen Fluoxetine-Treated OCD
  193. Is alternate‐day lithium really ineffective?
  194. AgNORs and their relationship to cell size, histological grade, lymph node involvement, metastases, and survival pattern in carcinoma of the breast: A study from south India
  195. BR-16A restricts development of electroconvulsive shock-induced retrograde amnesia
  196. BR-16A protects against ECS-induced anterograde amnesia
  197. Naltrexone and Alcohol Dependence: Some Methodological Issues
  198. Not significantly different is not the same as significantly similar